10.74%F 2.84 
5.58%SPY 86.07 4.46%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
MOUNTAIN VIEW, Calif. - Alexza Pharmaceuticals said Tuesday its experimental drug significantly reduced symptoms of schizophrenia in a late-stage trial.
| ALXA | 1.8 |  0.05 |
The company reported that a study of 344 schizophrenic patients showed AZ-004 significantly reduced agitation compared to placebo. Both a 5 and 10 milligram dose of the drug showed statistically significant results within two hours of treatment.
AZ-004 is an inhalable drug which Alexza is also studying as a potential treatment for migraine headaches.
Company executives said the drug's fast absorption and potential for self-administration would make it "a potentially important new drug candidate."
Shares of Alexza rose 10 cents to close at $5.41.
Toyota Motor Corp., the seemingly unstoppable juggernaut that saw its U.S. sales double in the last decade, has come back down to earth. Stung by...
Asian and European markets fell Monday as investors paused after last week's ral...
"Ugly Betty" star Vanessa Williams has kicked off a breast cancer fundraiser by driving a pink fence post into the ground in suburban New York Ci...
|
Split Big Profits! You Find it & We Fund it! Co-Own Or Cash Out! Get Free Info Kit Now!
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Building your business and corporate credit for your small business.
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
